Eli Lilly Becomes First Health-Care Company to Hit $1 Trillion Market Value

Eli Lilly made history on Friday by becoming the first health-care company in the world to reach a $1 trillion market valuation, marking a milestone previously dominated almost entirely by global tech giants.

The stock briefly crossed the trillion-dollar threshold in morning trading before easing back, last seen around $1,048 per share. Lilly is now the second U.S. non-tech company to join the trillion-dollar club, after Berkshire Hathaway.

The surge comes on the back of explosive demand for Zepbound, Lilly’s weight-loss injection, and Mounjaro, its blockbuster diabetes treatment. Both drugs have transformed the company’s financial trajectory and positioned it ahead of Danish rival Novo Nordisk in the fast-growing GLP-1 drug market.

Sales growth has been exceptional. In the most recent quarter, Mounjaro generated $6.52 billion, more than double the previous year, while Zepbound produced $3.59 billion, up 184%. Analysts expect demand to accelerate further as new approvals and wider insurance coverage roll out.

Lilly is also preparing to launch an oral version of its weight-loss and diabetes treatments next year, a move that could expand access and cut production complexity compared to injections.

The company’s dominance in the obesity-drug market is expected to hold, with some forecasts valuing the global sector at over $150 billion by the early 2030s. Competition remains strong, however: Novo Nordisk continues to invest heavily, and Pfizer recently secured a $10 billion deal for obesity-drug developer Metsera.

Founded in 1876, Lilly has a long history of breakthroughs, from the first commercial insulin to Prozac and early polio vaccines. But the runaway success of Mounjaro and Zepbound marks one of the most dramatic growth phases in its nearly 150-year existence.